Tymlos (abaloparatide; Radius Health) is a synthetic peptide analog of human parathyroid hormone-related protein (PTHrP), which binds to the same receptor as parathyroid hormone (PTH). Endogenous PTHrP plays a central role in the regulation of endochondral bone development, with knockout mice not surviving past birth due to lack of proper bone development. Despite binding to the same receptor (PTHR1), PTHrP and PTH have different functions in vivo. Although they both act to increase BMD, PTHrP does not induce the subsequent unwanted bone resorption or hypercalcemic responses to the same extent as is seen with PTH. Compared with PTH, Tymlos has been shown to bind with a greater affinity to the conformation of PTHR that positively impacts bone formation.
LIST OF FIGURES
8 Figure 1: Datamonitor Healthcare’s drug assessment summary of Tymlos transdermal patch for osteoporosis
9 Figure 2: Datamonitor Healthcare’s drug assessment summary of Tymlos transdermal patch for osteoporosis
LIST OF TABLES
6 Table 1: Tymlos transdermal patch drug profile
7 Table 2: Tymlos transdermal patch for osteoporosis – SWOT analysis
Datamonitor Healthcare is part of Pharma intelligence
Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726